Compare FINV & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | ARDX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.1M | 724.0M |
| IPO Year | 2017 | 2014 |
| Metric | FINV | ARDX |
|---|---|---|
| Price | $2.85 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $5.62 | ★ $12.50 |
| AVG Volume (30 Days) | 788.1K | ★ 4.6M |
| Earning Date | 11-25-2026 | 11-03-2026 |
| Dividend Yield | ★ 11.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | N/A | $26.08 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.66 | $2.80 |
| 52 Week High | $6.39 | $8.40 |
| Indicator | FINV | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 48.00 |
| Support Level | N/A | $2.96 |
| Resistance Level | $3.06 | $3.38 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 48.62 | 49.18 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.